Development of novel biomarkers to guide selection of pharmacological treatment in patients with ADHD

ADHD is characterized by the inability to (i) focus and sustain attention and (ii) extert top-down control over behaviour. Roughly 3 of the adult population meets criteria for ADHD. Treatment is multimodal with a combination of pharmacological and non-pharmacological interventions. Central stimulants (CS) are the mainstay of pharmacological treatment and are divided into methylphenidate and amphetamine. There are huge individual differences in the response to these mediciations. The purpose of our project is to investigate whether it is possible to develop a method that with the help of machine learning based on clinical outcome measures, fMRI, genetic variability and study of tyrosine transport accorss membranes can predict whether a specificmedication will have an intended effect in a given individual.